Summary by Futu AI
On October 2, 2024, Recursion Pharmaceuticals, Inc., a clinical stage TechBio company, announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for REC-1245, a potential first-in-class RBM39 Degrader aimed at treating biomarker-enriched solid tumors and lymphoma. The company plans to initiate a Phase 1/2 clinical trial in Q4 2024 to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and potential efficacy of REC-1245 as a monotherapy. REC-1245 was developed using Recursion's AI-enabled platform, which facilitated the identification and optimization of the drug candidate in under 18 months, significantly faster than the industry average. The company's platform leverages machine learning algorithms and one of the world's most powerful supercomputers to analyze vast biological and chemical datasets. Recursion Pharmaceuticals, headquartered in Salt Lake City, is also a founding member of BioHive, the Utah life sciences industry collective.
